94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1517223
This article is part of the Research Topic Metabolism Dysregulation in Hematologic Malignancies View all articles
Prognostic and clinicopathological value of the controlling nutritional status (CONUT) score in patients with multiple myeloma: a metaanalysis
Provisionally accepted
Yin Jin 
Wenfei Gu *- Huzhou Central Hospital, Huzhou, China
Background: The effect of controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results remained inconsistent. The present meta-analysis focused on identifying the exact function of CONUT in forecasting MM prognosis.Methods: Web of Science, PubMed, Embase, CNKI and Cochrane Library were comprehensively searched between inception and February 01, 2025. The effect of CONUT on forecasting MM overall survival (OS) and progression-free survival (PFS) was determined by computing pooled hazard ratios (HRs) together with 95% confidence intervals (CIs).Results: There were nine studies with 1176 cases patients being recruited into the present work. As indicated by our pooled data, elevated CONUT was related to the dismal OS (HR=1.87, 95%CI=1.37-2.54, p<0.001) of patients with MM. Nonetheless, CONUT was not significantly related to PFS (HR=1.33, 95%ci=0.81-2.19, p=0.254) of MM. Furthermore, higher CONUT score showed significant relation to bone marrow plasma cells >30% (OR=2.30, 95%CI=1.32-3.99, p=0.003). Whereas CONUT was not markedly correlated with gender (OR=2.68, 95%CI=0.81-8.82, p=0.105), ISS stage (OR=1.28, 95%CI=0.94-1.75, p=0.119), or ECOG PS (OR=1.30, 95%CI=0.84-2.01, p=0.234) of MM.Conclusion: Collectively, according to our results in this meta-analysis, higher CONUT score is markedly related to dismal OS, but not PFS in patients with MM. CONUT score can be used as the candidate marker used to predict MM prognosis in clinic in the future.
Keywords: CONUT score, Multiple Myeloma, Meta-analysis, Evidence-Based Medicine, prognosis
Received: 25 Oct 2024; Accepted: 28 Feb 2025.
Copyright: © 2025 Jin and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenfei Gu, Huzhou Central Hospital, Huzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.